{"companyId":366854,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","es","ja"],"companyName":"Oryzon Genomics, S.A.","headOfficeLocation":"Sant Ferran 74, Cornellà de Llobregat, 08940, Spain","presidentName":"Carlos Manuel Buesa Arjol","companySummary":null,"stockCode":"ORY","currency":"EUR","capital":null,"sales":null,"employees":46,"employeesConsolidated":null,"humanCheck":false,"domains":["oryzon.com"],"businessContents":["Epigenetics-based drug discovery biopharmaceutical business (cancer and central nervous system diseases)"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://stockanalysis.com/quote/bme/ORY/company/","scoreAbout":60,"scoreBusiness":60,"scoreGroup":0,"scoreCustomer":0}]}